Orally disintegrating pharmaceutical compositions with sensory cue agents
The present invention relates to pharmaceutical compositions that disintegrate in the mouth and include at least one systemically active pharmaceutical ingredient in a therapeutically effective amount and at least one sensory cue agent in a sensory effective amount.
1 . A pharmaceutical composition comprising:
(a) at least one systemically active pharmaceutical ingredient in a therapeutically effective amount; and
(b) at least one sensory cue agent in a sensory cue effective amount;
wherein said pharmaceutical composition is designed to disintegrate in the buccal cavity in less than about 60 seconds.
2 . The composition of claim 1 wherein the sensory cue agent is selected from the group consisting of menthol oil, menthol crystals, mannitol, eucalyptus oil, eucalyptol, thymol, camphor, spearmint, cinnamon, mint, ginger, wintergreen (methyl salicylate), peppermint, carboxamides, acyclic carboxamides, 3-1-menthoxy propane-1,2-diol, N-substituted-p-menthane-3-carboxamides, N-ethyl-p-menthane-3-carboxamide, N,2,3-trimethyl-2-isopropylbutanamide and combinations thereof.
3 . The composition of claim 1 wherein said sensory cue agent is present in an amount from about 2 mg to about 15 mg.
4 . The composition of claim 1 wherein said sensory cue agent is present in an amount from about 0.001% to about 15% by weight of the pharmaceutical composition.
5 . The composition of claim 1 wherein said composition disintegrates in said mouth in less than 30 seconds.
6 . The composition of claim 1 wherein said sensory cue agent is menthol.
7 . The composition of claim 1 wherein said sensory cue agent comprises menthol and eucalyptus.
8 . The composition of claim 1 wherein said active pharmaceutical agent is selected from the group consisting of phenylephrine, pseudoephedrine, phenylpropanolamine, ephedrine, dextromethorphan, diphenhydramine, a prodrug thereof, an isomer thereof, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of said prodrug thereof and combinations thereof.
9 . The composition of claim 8 wherein said pseudoephedrine is present in an amount of from about 15 mg to about 360 mg.
10 . The composition of claim 8 wherein said phenylephrine is present in an amount from about 2.5 mg to about 50 mg.
11 . The composition of claim 8 wherein said dextromethorphan is present in an amount from about 2.5 mg to about 50 mg.
12 . The composition of claim 8 wherein said diphenhydramine is present in an amount from about 2.5 mg to about 50 mg.
13 . The composition of claim 1 , wherein said active pharmaceutical ingredient is selected from the group consisting of phenylephrine, pseudoephedrine, phenylpropanolamine, ephedrine, dextromethorphan, diphenhydramine, a prodrug thereof, an isomer thereof, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of said prodrug thereof and combinations thereof and wherein said sensory cue agent is selected from the group consisting of menthol oil, menthol crystals, mannitol, eucalyptus oil, eucalyptol, thymol, camphor, spearmint, cinnamon, mint, ginger, wintergreen (methyl salicylate), peppermint, carboxamides, acyclic carboxamides, 3-1-menthoxy propane-1,2-diol, N-substituted-p-menthane-3-carboxamides, N-ethyl-p-menthane-3-carboxamide, N,2,3-trimethyl-2-isopropylbutanamide and combinations thereof.
14 . The composition of claim 1 wherein said composition is in a dosage form selected from the group consisting of a tablets, soft or hard capsules, gels, caplets, wafers, ovules, granules, buccal/mucoadhesive patches, powders, freeze dried (lyophilized) wafers, chewable tablets, single layer stand alone films, dry multiple layer stand alone films and combinations thereof.
15 . The composition according to claim 1 wherein the systemically active pharmaceutical ingredient is selected from the group consisting of antihistamines, decongestants, antitussives, anesthetics, expectorants, demulcents, immune stimulators, vitamins, antibiotics, antiseptics, analgesics, bronchodilators, and combinations thereof.
16 . The composition according to claim 1 wherein the systemically active pharmaceutical ingredient is selected form the group consisting of pseudoephedrine, phenyleprine, dextromethorphan, benzocaine, cetacaine, lidocaine, cetylpyridinium chloride, diphenhydramine, chlorpheniramine, acetaminophen, ibuprofen, aspirin, naproxen, celecoxib, valdecoxib, rofecoxib, brompheniramine, dexbrompheniramine, tripolidine, dexchlorpheniramine, chlorcyclizine, triprolidine, doxylamine, carbinoxamine, azatadine; tripelennamine, alimemazine, bromodiphenhydramine, phenindamine, pyrilamine, loratadine, desloratadine, fexofenadine, cetirizine, acrivastine, levocetirizine, mizolastine, codeine, carbetapentane, caramiphen, noscapine, clofedanol, guaifenesin, bromhexine, carbocysteine, terpin hydrate, potassium guaicolsulfonate, zinc, glycerin, honey, vitamin C, vitamin E, methylxanthines, epinephrine, racepinephrine, cetapyridium, cephalexin, amoxicillin, phenol and combinations thereof.
17 . A pharmaceutical composition comprising:
(a) at least one systemically active pharmaceutical ingredient in a therapeutically effective amount; wherein said active pharmaceutical ingredient is selected from the group consisting of phenylephrine, pseudoephedrine, dextromethorphan, diphenhydramine and combinations thereof and
(b) at least one sensory cue agent in a sensory cue effective amount; wherein said sensory cue agent is selected from the group consisting of menthol oil, menthol crystals, mannitol, eucalyptus oil, eucalyptol, thymol, camphor, spearmint, cinnamon, mint, ginger, wintergreen (methyl salicylate), peppermint, carboxamides, acyclic carboxamides, 3-1-menthoxy propane-1,2-diol, N-substituted-p-menthane-3-carboxamides, N-ethyl-p-menthane-3-carboxamide, N,2,3-trimethyl-2-isopropylbutanamide and combinations thereof;
wherein said pharmaceutical composition is a tablet designed to disintegrate in the buccal cavity in less than about 60 seconds.
18 . The composition of claim 17 , wherein said sensory cue agent is selected from the group consisting of menthol and eucalyptol and combinations thereof.
19 . A method for treating upper respiratory ailments in humans and animals, comprising administering a composition according to claim 17 to a patient in need of such treatment.
20 . A packaged kit for a patient comprising:
a housing of a plurality of oral dosage forms comprising a pharmaceutical composition comprising:
(a) at least one systemically active pharmaceutical ingredient in a therapeutically effective amount; and
(b) at least one sensory cue agent in a sensory cue effective amount;
wherein said pharmaceutical composition is designed to disintegrate in the buccal cavity in less than about 60 seconds, and;
instructions for carrying out drug administration therewith.